Mental Health, Work Productivity, and Quality of Life in People with Severe Haemophilia A Receiving Prophylaxis: Findings from the CHESS Data Platform
Patients receiving emicizumab prophylaxis appeared to have more favourable mental health, work productivity, and HRQoL-related outcomes than those receiving FVIII prophylaxis. These findings were observed in the context of comparable clinical characteristics between emicizumab and FVIII prophylaxis despite evidence of a more complex treatment history for the emicizumab group. This analysis has limitations, including a lack of adjustment for confounding factors.
Authors
- Enrico Ferri Grazzi (ORCID: https://orcid.org/0000-0002-0567-0260)
- Letizia Polito (ORCID: https://orcid.org/0000-0001-7014-9677)
- Tom Blenkiron (ORCID: https://orcid.org/0000-0002-5716-0748)
- Michael Oellerich (ORCID: https://orcid.org/0000-0002-9255-2261)
- Tom Burke (ORCID: https://orcid.org/0000-0001-6768-1670)
- Pratima Chowdary (ORCID: https://orcid.org/0000-0002-6690-8586)
- Romain Chafaie
Institutions
- Roche (Switzerland) (CH)
- University of Chester (GB)
- Royal Free London NHS Foundation Trust (GB)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- University College London (GB)
Publication Details
- Journal
- TH Open
- Published
- 2025-08-04
- DOI
- https://doi.org/10.1055/a-2658-6151
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- F. Hoffmann-La Roche